Vatalanib Dihydrochloride

Name: Vatalanib Dihydrochloride
SKU: V0376
Availability: InStock

Product ID V0376

Cas No. 212141-51-0

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

Vatalanib is an inhibitor of VEGFR that is currently in clinical trials for the treatment of myelodysplastic syndrome, lymphomas, non-small cell lung cancers (NSCLCs), and other cancers. Vatalanib exhibits anti-angiogenic, anti-metastatic, anticancer chemotherapeutic, and analgesic activities. In animal models with mammary carcinoma allografts, vatalanib decreases tumor vascularization. In animal models of pancreatic carcinoma, vatalanib inhibits tumor growth and metastasis and decreases microvessel density. Additionally, vatalanib decreases chronic neuropathic pain in animal models of chronic constriction injury, as inhibition of VEGFR2 inhibits signaling through neuropathic pain-mediating P2X (2/3) receptors.

Product Info

Cas No.	212141-51-0
Purity	≥98%
Formula	C₂₀H₁₅ClN₄ • 2HCl
Formula Wt.	419.73
IUPAC Name	N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochloride
Synonym	PTK-787 Dihydrochloride, PTK 787 Dihydrochloride, PTK787 Dihydrochloride, ZK-222584 Dihydrochloride, ZK 222584 Dihydrochloride, ZK222584 Dihydrochloride, CGP-797870 Dihydrochloride, ZK232934 Dihydrochloride
Melting Point	268-270°C
Appearance	Off-white to pinkish powder

Shipping and Storage

Store Temp	Ambient
Ship Temp	Ambient

Downloads

MSDS	V0376 MSDS PDF
Info Sheet	V0376 Info Sheet PDF

References

Gupta P, Mulkey F, Hasserjian RP, et al. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct;31(5):1311-20. PMID: 23700288.

Liu S, Xu C, Li G, et al. Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats. Neurochem Int. 2012 May;60(6):565-72. PMID: 22361062.

Gauler TC, Besse B, Mauguen A, et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol. 2012 Mar;23(3):678-87. PMID: 21617019.

Hlushchuk R, Riesterer O, Baum O, et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol. 2008 Oct;173(4):1173-85. PMID: 18787105.

Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm. 2001 Oct;16(5):359-70. PMID: 11776753.